Feed ALVO
AL

Alvotech

ALVO · NASDAQ

$5.02 -0.59% (-$0.03)
1M +29.38%
Market Cap $1.70B
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$6.84

36.3% upside

Current Price

$5.02

Undervalued Fair Value Overvalued

According to Bulios Fair Price, ALVO is currently undervalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
0/9
Valuation
51 /100
Fair
P/S 3.45x
P/FFO N/A
P/B N/A
Growth
100 /100
Growing
Rev. growth 91.85%
FCF growth N/A
Book val. growth N/A
Profitability
32 /100
Weak
Net margin 36.51%
Op. margin 9.62%
FCF margin 61.03%
Quality
63 /100
Average
ROA 11.31%
Asset turnover 0.31x
ROIC 20.17%
Debt
35 /100
Moderate
Int. coverage -0.22x
Current ratio 1.65x
Net debt/EBITDA N/A
Stability
13 /100
Unstable
Rev. volatility 242.90%
EPS volatility 52.56%
Profitable years 1

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ALVO
Online

About the company

Alvotech (ALVO) is a fully integrated specialty biopharmaceutical company focused exclusively on the development and manufacture of high-quality biosimilar medicines. The company's goal is to improve patients' health and quality of life around the world by increasing access to effective therapies for various ailments.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Lisa Graver

Employees

1,279

Headquarters

Luxembourg

Upcoming events

11 NOV

Earnings

Upcoming earnings report

56d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.